Press Releases

Date Title and Summary
Toggle Summary New Data Demonstrating TomoTherapy® System Adaptive Capabilities and Workhorse Reliability Presented at Leading Scientific Meeting for Medical Physicists
Clinical Research Also Showcases Innovative Approaches to Expanding TomoTherapy Platform Functionality SUNNYVALE, Calif. , Aug. 4, 2016 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that new studies demonstrating the TomoTherapy® System's leading-edge adaptive therapy
Toggle Summary New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis. , March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery
Toggle Summary New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies SUNNYVALE, Calif. , May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife®  and
Toggle Summary New Data Presented at ESTRO 36 Reinforce Unmatched Versatility and Precision of the CyberKnife® System
Studies Show the System Provides Excellent Outcomes Throughout the Cancer Treatment Journey, from Primary Cases to Recurrence and Metastatic Disease SUNNYVALE, Calif. , May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies on the clinical use of the
Toggle Summary New Data Reinforce Benefits of TomoTherapy® Platform for Mainstream Radiation Therapy Treatment Indications
Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities SUNNYVALE, Calif. , May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the unmatched flexibility of the cutting-edge
Toggle Summary New Data Show InCise™ Multileaf Collimator for the CyberKnife® M6™ System may Expand Patient Population Eligible for Precise Radiation Treatments
Clinical Research on the CyberKnife® System, Including the Multileaf Collimator, Presented at Leading Scientific Meeting for Medical Physicists SUNNYVALE, Calif., August 4, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today that more than 45 studies on the use of the  CyberKnife®
Toggle Summary New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNNYVALE, Calif.
Toggle Summary New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
Updated ASTRO Model Policy Endorses Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer SUNNYVALE, Calif. , May 21, 2013 /PRNewswire/ --   Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the
Toggle Summary New Reimbursement Approved by the Japanese Ministry of Health, Labor and Welfare for the Accuray CyberKnife® System to Treat Trigeminal Neuralgia, a Condition Often Causing Severe Facial Pain
SUNNYVALE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife ® System for the treatment of trigeminal neuralgia (TN).
Toggle Summary New Studies Show the Accuray TomoTherapy® System Provides Greater Precision, Excellent Clinical Outcomes in Patients Undergoing Total Body Irradiation
SUNNYVALE, Calif. , May 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy ® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.